Tatsis Ourania — SEC Form 4 filings
SEC reporting owner CIK 1789815. 28 Form 4 filings on record with FilingPulse; latest filed 2026-07-23.
Transaction summary — filings shown
Covers all 28 filings on record, filed 2024-02-08 to 2026-07-23. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 21 legs across 19 filings — 30,724 shares, $14,450,269 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 27.
- Largest priced transaction: sale of 4,500 shares @ $474.99 ($2,137,455) in VERTEX PHARMACEUTICALS INC / MA, filed 2026-01-09.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | EVP, Chief Reg. & Quality Off. | 24 | — | 21 legs · 30,724 sh · $14,450,269 | 22 |
| Verve Therapeutics, Inc. (VERV) | Director | 3 | — | — | 4 |
| Odyssey Therapeutics, Inc. (ODTX) | Director | 1 | — | — | 1 |
Form 4 filings — Tatsis Ourania
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-23 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 8,251 @ $0 | EDGAR |
| 2026-07-07 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Sale (S): 1,500 @ $524.99 | EDGAR |
| 2026-05-11 | 4 | Odyssey Therapeutics, Inc. (ODTX) | Grant/award (A): 27,393 (derivative) @ $0 | EDGAR |
| 2026-02-26 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 1,627 @ $485.11 · Sale (S): 260 @ $486.35 | EDGAR |
| 2026-02-19 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 5,789 @ $0 · Tax withholding (F): 2,294 @ $483.75 · Sale (S): 609 @ $489.46 · Sale (S): 368 @ $473.68 | EDGAR |
| 2026-02-18 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 3,804 @ $487.76 · Sale (S): 1,500 @ $499.99 | EDGAR |
| 2026-02-12 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 2,140 @ $468.41 · Sale (S): 466 @ $460.43 | EDGAR |
| 2026-01-26 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 7,866 @ $0 · Grant/award (A): 3,883 @ $0 | EDGAR |
| 2026-01-09 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Sale (S): 4,500 @ $474.99 | EDGAR |
| 2025-12-05 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Sale (S): 4,500 @ $449.99 | EDGAR |
| 2025-07-28 | 4 | Verve Therapeutics, Inc. (VERV) | Disposition to issuer (D): 267,541 (derivative) · Disposition to issuer (D): 42,200 (derivative) | EDGAR |
| 2025-06-06 | 4 | Verve Therapeutics, Inc. (VERV) | Grant/award (A): 42,200 (derivative) @ $0 | EDGAR |
| 2025-03-12 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Sale (S): 3,242 @ $499.99 | EDGAR |
| 2025-03-06 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Sale (S): 4,058 @ $485.49 | EDGAR |
| 2025-02-28 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 4,962 @ $479.61 · Sale (S): 530 @ $475.34 | EDGAR |
| 2025-02-26 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 3,310 @ $483.28 · Sale (S): 354 @ $480.95 | EDGAR |
| 2025-02-19 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 2,293 @ $463.46 · Sale (S): 244 @ $455.06 | EDGAR |
| 2025-02-14 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 6,211 @ $0 | EDGAR |
| 2025-02-12 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 2,143 @ $467.98 · Sale (S): 310 @ $459.83 | EDGAR |
| 2025-02-06 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 10,262 @ $0 · Grant/award (A): 7,114 @ $0 | EDGAR |
| 2024-06-28 | 4 | Verve Therapeutics, Inc. (VERV) | Grant/award (A): 267,541 (derivative) @ $0 | EDGAR |
| 2024-06-05 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Sale (S): 2,175 @ $460 | EDGAR |
| 2024-06-03 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Sale (S): 2,350 @ $439.11 · Sale (S): 2,250 @ $445 | EDGAR |
| 2024-02-27 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 3,309 @ $431.79 · Sale (S): 354 @ $425.70 | EDGAR |
| 2024-02-23 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Sale (S): 360 @ $421.77 | EDGAR |
| 2024-02-21 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 4,499 @ $424.01 · Tax withholding (F): 3,373 @ $420.58 · Sale (S): 480 @ $420.79 | EDGAR |
| 2024-02-13 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 2,100 @ $422.74 · Sale (S): 314 @ $420.24 | EDGAR |
| 2024-02-08 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 6,976 @ $0 · Grant/award (A): 7,866 @ $0 · Grant/award (A): 7,114 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1789815 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →